StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.79−0.08 (-0.27%)

Close on Nov 18, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

UroGen Pharma's total debt was $188.73M at Jun 30, 2026. For fiscal 2025 it was $122.21M, up 0.4% from the year before. The highest annual figure on record is $122.21M in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$122.21M+0.4%
FY2024Dec 31, 2024$121.73M+23.5%
FY2023Dec 31, 2023$98.55M+1.0%
FY2022Dec 31, 2022$97.54M–
FY2021Dec 31, 2021$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$188.73M+54.1%
Q1 FY2026Mar 31, 2026$189.53M+55.2%
Q4 FY2025Dec 31, 2025$122.21M+0.4%
Q3 FY2025Sep 30, 2025$122.11M+0.3%
Q2 FY2025Jun 30, 2025$122.51M+25.2%
Q1 FY2025Mar 31, 2025$122.11M+25.1%
Q4 FY2024Dec 31, 2024$121.73M+23.5%
Q3 FY2024Sep 30, 2024$121.71M+23.5%
Q2 FY2024Jun 30, 2024$97.81M-0.5%
Q1 FY2024Mar 31, 2024$97.59M-0.4%
Q4 FY2023Dec 31, 2023$98.55M+1.0%
Q3 FY2023Sep 30, 2023$98.52M+37.1%
Q2 FY2023Jun 30, 2023$98.30M+38.1%
Q1 FY2023Mar 31, 2023$97.94M+38.3%
Q4 FY2022Dec 31, 2022$97.54M–
Q3 FY2022Sep 30, 2022$71.87M–
Q2 FY2022Jun 30, 2022$71.20M–
Q1 FY2022Mar 31, 2022$70.80M–
Q4 FY2021Dec 31, 2021$0–

More UroGen Pharma figures

See a number that looks wrong?